Published in Medicine and Law Weekly, October 20th, 2006
Study 1: Advanced cancer patients could be safely administered NV06 (Phenoxodiol) over 1-2 h at a dose of at least 30 mg/kg.
According to recent research from Australia, "We wished to define the maximum tolerated dose (MTD), toxicity, and pharmacokinetics of the novel isoflav-3-ene, NV06, a compound with a diphenolic structure related chemically and biologically to genistein and flavopiridol. Twenty-one patients with advanced cancers were treated with weekly intravenous administration of NV06 at escalating dose levels with 1-4 patients at each dose cohort. Plasma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly